Abstract
Wastewater-based epidemiology (WBE) was utilized to monitor SARS-CoV-2 RNA in sewage collected from manholes specific to individual student dormitories (dorms) at the University of Arizona in the fall semester of 2020, which led to successful identification and reduction of transmission events. Positive wastewater samples triggered clinical testing of almost all residents within that dorm; thus, SARS-CoV-2 infected individuals were identified regardless of symptom expression. This current study examined clinical testing data to determine the abundance of asymptomatic versus symptomatic cases in these defined communities. Nasal and nasopharyngeal swab samples processed via antigen and PCR tests indicated that 79.2% of SARS-CoV-2 infections were asymptomatic, and only 20.8% of positive cases reported COVID- 19 symptoms at the time of testing. Clinical data was paired with corresponding wastewater virus concentrations, which enabled calculation of viral shedding rates in feces per infected person(s). Mean shedding rates averaged from positive wastewater samples across all dorms were 6.84 ± 0.77 log10 genome copies per gram of feces (gc/g-feces) based on the N1 gene and 7.74 ± 0.53 log10 gc/g-feces based on the N2 gene. Quantification of SARS-CoV-2 fecal shedding rates from infected persons has been the critical missing component necessary for WBE models to measure and predict SARS-CoV-2 infection prevalence in communities. The findings from this study can be utilized to create models that can be used to inform public health prevention and response actions.
Highlights
Wastewater-based epidemiology with clinical testing monitored SARS-CoV-2 in dorms.
79.2% of SARS-CoV-2 infections were asymptomatic, and 20.8% were symptomatic.
Clinical and wastewater data aggregated to estimate SARS-CoV-2 fecal shedding rate.
Mean fecal shedding rate based on the N1 gene was 6.84 ± 0.77 log10 gc/g-feces.
Mean fecal shedding rate based on the N2 gene was 7.74 ± 0.53 log10 gc/g-feces.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for the study was provided by the University of Arizona Campus Re-Entry Task Force.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Arizona IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request.
